Research Article

Treatment of Diabetic Macular Edema with Intravitreal Antivascular Endothelial Growth Factor and Prompt versus Deferred Focal Laser during Long-Term Follow-Up and Identification of Prognostic Retinal Markers

Table 2

Functional ((best-corrected visual acuity (BCVA)) and morphological (central retinal thickness (CRT)) results in eyes with diabetic macular edema (DME, 50 eyes, top) treated with intravitreal ranibizumab and immediate focal laser therapy (prompt group, 25 eyes, middle) and eyes treated with intravitreal ranibizumab and deferred laser (25 eyes, bottom).

Baseline6 weeks12 weeks18 weeks6 months9 months1 year2 years3 years4 years5 years

Entire study population
BCVA0.320,500.500.500.500.500.500.720.670.620.68
SD0.030,030.030.040.040.030.030.420.260.260.25
logMAR (Snellen)0.50 (20/40)0.30 (20/63)0.30 (20/63)0.30 (20/63)0.30 (20/63)0.30 (20/63)0.30 (20/63)0.20 (20/100)0.25 (20/80)0.30 (20/63)0.20 (20/100)
CRT457.20401.6391.3381.10269.60358.90351.90377.40363.00343.80348.30
SD90.7098.4094.2099.3085.7088.3093.00108.2095.2078.7062.00

Prompt treatment group
BCVA0.320.500.500.400.040.500.500.700.630.580.58
SD0.030.040.040.050.040.030.030.390.360.290.31
logMAR (Snellen)0.50 (20/40)0.30 (20/63)0.30 (20/63)0.40 (20/50)0.40 (20/50)0.30 (20/63)0.30 (20/63)0.20 (20/100)0.20 (20/100)0.30 (20/63)0.30 (20/63)
CRT460.30381.60399.40370.20360.70362.80354.70360.70360.70357.00354.40
SD87.4070.2091.50113.50101.50106.1094.10105.80106.90108.00108.90

Deferred treatment group
BCVA0.320.500.400.400.400.400.500.610.560.530.61
SD0.030.030.040.050.040.040.030.350.300.290.31
logMAR (Snellen)0.50 (20/40)0.30 (20/63)0.40 (20/50)0.40 (20/50)0.40 (20/50)0.40 (20/50)0.30 (20/63)0.30 (20/63)0.30 (20/63)0.30 (20/63)0.30 (20/63)
CRT454.10389.70382.00370.20360.70348.80340.90363.40352.40342.10327.60
SD95.60114.80110.10113.50101.50106.10114.80111.10107.30104.5069.70

Note. BCVA = best-corrected visual acuity, SD = standard deviation, and CRT = central retinal thickness.